Today, I’ll be spending the day at my longevity clinic in Manhattan.
That means a full schedule of tests, scans, blood work, and checkups designed to identify potential health issues long before they become serious problems.
And as I sat down to write today’s Market Insights, it struck me that this experience highlights one of the most overlooked investment opportunities in the market today.
Preventative medicine.
For decades, healthcare has largely been reactive.
People get sick. They develop symptoms. Then doctors attempt to diagnose and treat the problem.
This is Sick Care NOT Health Care
But what if we could identify many diseases years before symptoms appear? What if healthcare shifted from treating illness to preventing it?
That is exactly where medicine is heading — and it could create enormous opportunities for investors over the next decade.
The numbers alone are staggering.
The United States spends more than $4 trillion annually on healthcare. Yet much of that spending occurs after diseases have already advanced.
Cancer, heart disease, diabetes, and neurodegenerative disorders account for trillions of dollars in healthcare costs globally each year.
Even modest improvements in early detection could save governments, insurers, employers, and patients hundreds of billions of dollars.
That is why some of the smartest minds in medicine and technology are focused on one goal: finding diseases earlier.
The Race to Detect Disease Before It Starts
One of the most exciting areas is cancer detection.
Traditionally, cancer screening has relied on individual tests for specific cancers — mammograms for breast cancer, colonoscopies for colon cancer, PSA tests for prostate cancer. But a new generation of companies is attempting something much bigger: identifying dozens of cancers from a simple blood sample.
Perhaps the best-known company in this field is Grail (GRAL). Its Galleri test is designed to detect signals associated with multiple types of cancer from a single blood draw.
Another leader is Guardant Health (GH), which has developed liquid biopsy technology that helps identify cancer-related genetic mutations through blood testing.
Meanwhile, Exact Sciences (EXAS) has already transformed colorectal cancer screening through its Cologuard test and continues expanding its diagnostic capabilities.
The long-term vision is compelling.
Imagine visiting your doctor for an annual physical. Alongside standard blood work, you receive a comprehensive screening panel capable of identifying cancer, cardiovascular disease risk, metabolic disorders, and other health concerns years before symptoms emerge.
That future may sound ambitious today, but many of the technologies already exist.
Artificial intelligence is accelerating the trend even further.
AI Is Turbocharging Early Detection
AI systems can analyze medical images, pathology slides, genetic data, and blood biomarkers at a scale that was impossible just a few years ago.
Companies such as Tempus AI (TEM) are using AI to help physicians interpret massive amounts of clinical and genomic data. The goal is not only better treatment decisions but earlier detection and more personalized healthcare.
And cancer is only one piece of the puzzle.
Preventative cardiology is advancing rapidly. Continuous glucose monitoring is becoming more common even among non-diabetics. Advanced imaging technologies can identify plaque buildup in arteries years before a heart attack occurs.
Many longevity clinics are already incorporating full-body MRI scans, extensive biomarker testing, genetic analysis, and advanced cardiovascular screening into routine care.
From Early Adopters to Everyday Medicine
Today these services are still used primarily by affluent individuals and early adopters — but so were smartphones, so were electric vehicles, and so was cloud computing.
Over time, costs decline, technology improves, and adoption expands.
The same pattern could play out in preventative medicine.
In fact, I believe we are approaching a point where annual advanced health screenings become as common as routine blood work is today.
The investment implications could be significant. Investors often focus on the companies developing breakthrough drugs, and rightly so.
But some of the biggest winners in healthcare over the next decade may come from a different corner of the market - companies helping people avoid disease in the first place.
The shift from reactive healthcare to proactive healthcare is still in its early innings.
Just as AI is transforming technology and robotics is transforming manufacturing, preventative medicine could transform healthcare.
And if that happens, investors who recognize the trend early may be rewarded handsomely.
Because the future of healthcare may not be about treating disease.
It may be about preventing it altogether.
Companies Benefiting From the Preventative Medicine Trend
The opportunity extends well beyond cancer screening. Here are several other companies I believe investors should keep on their radar as healthcare shifts toward prevention, early detection, and longevity:
Illumina (ILMN)
Often called the “picks and shovels” of genomics, Illumina provides the sequencing technology that powers much of the genetic testing industry. As DNA testing becomes a routine part of healthcare, Illumina stands to benefit from growing demand across diagnostics, research, and personalized medicine.
Natera (NTRA)
Natera specializes in blood-based genetic testing for cancer detection, organ transplant monitoring, and prenatal screening. The company’s Signatera test is becoming an increasingly important tool for detecting cancer recurrence before traditional imaging can identify it.
DexCom (DXCM)
Continuous glucose monitors are no longer just for diabetics. More consumers are using these devices to optimize health, track metabolic performance, and better understand how diet impacts their bodies. This could become a standard wellness tool in the years ahead.
Butterfly Network (BFLY)
Butterfly is attempting to make medical imaging as accessible as taking a blood pressure reading. Its handheld ultrasound devices connect to smartphones and could dramatically expand access to early screening and preventative care around the world.
Bottom Line
Taken together, these companies represent different pieces of what could become one of the biggest healthcare transformations of our lifetime.
The future may belong not only to the companies that cure disease, but also to those that help us detect and prevent it before it ever becomes a problem.
Here’s to the future,
Matt McCall
Founder, NXT Wave Research
